Trial
NCT00869323
Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
Millennium Pharmaceuticals, Inc.
Condition
Lymphoproliferative Disorder
Intervention
rituximab
Why stopped
Funding unavailable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-05